Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

-- 46% of Evaluable Patients Show Stabilized Disease; Biomarkers Correlate with Clinical Effect and Demonstrate Potential for Patient Stratification --

GERMANTOWN, Md., June 19, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced continued positive interim results from its Phase I study of AVN944, for the treatment of hematologic malignancies in elderly and refractory patients. Interim data indicate AVN944 is well tolerated, has dose-dependent pharmacokinetics, induces biomarkers of programmed cell death in cancer cells from patients, and demonstrates stabilized disease in almost half of the patients after one-month of treatment.

"We continue to be encouraged by the positive interim results from the AVN944 trial," stated Michael Hamilton, M.D., Avalon Pharmaceuticals' Chief Medical Officer. "We have observed important indications of biological drug effect and disease stabilization in a significant number of patients. We continue to believe the Phase I trial will provide sufficient information to initiate multiple Phase II studies."

Background: AVN944 is an oral small molecule drug that inhibits inosine monosphospate dehydrogenase (IMPDH), a critical enzyme for synthesis of guanosine triphosphate (GTP), a molecule required for DNA synthesis and cellular signaling. IMPDH is over expressed in many cancer cells. Pre-clinical studies showed that AVN944 is a highly specific inhibitor of IMPDH, suppresses pools of GTP, and in cultured cells has a selective growth inhibition effect on cancer cells vs. normal cells.

An earlier single-dose, dose-escalation, healthy volunteer clinical trial conducted in the United Kingdom showed that AVN944 was well tolerated at all tested doses with no notable side effects; had good pharmacokinetic properties; and had a significant inhibitory effect on IMPDH enzyme activity.

Study Design: The current U.S. Phase I study is a repeat-dos e dose escalation trial in patients with advanced hematologic malignancies. Patients are dosed for 21 days on a 28-day cycle. A minimum of three patients are treated at each dose level. The study is divided into two arms, one for treatment of leukemia patients and the other for treatment of patients with lymphoma and myeloma. For the leukemia arm of the study, patients are currently being treated at the tenth dose level, 250 mg twice daily. For the lymphoma and myeloma arm, patients are currently being treated at the sixth dose level, 150 mg twice daily.

Positive Safety and Tolerability Data: The goal of the Phase I study is to establish the safety, tolerability and pharmacokinetics of the drug. Thus far, 104 one-month cycles of AVN944 have been initiated in 46 patients and the compound is well tolerated. Pharmacokinetics measurements indicate dose proportional plasma levels of AVN944 during treatment and sustained plasma concentrations at the dose levels tested thus far.

Early Activity Indicators: This Phase I study is designed to evaluate several pharmacodynamic and efficacy-related endpoints. Upon entering the trial, all patients have refractory, progressive disease and have failed all prior therapies. Thus far, 18 of 39 evaluable patients (46%) showed stabilized disease after one cycle of treatment with AVN944. These include patients with both leukemia and multiple myeloma. Patients who have achieved stable disease following completion of a one-month treatment cycle with AVN944, as determined by the clinical investigator, may be advanced to a subsequent cycle.

In the multiple myeloma cohort 60% of the patients have achieved stabilized disease after one month. Two of these patients completed five months of treatment and two others completed one full year of treatment. One AML patient has completed 8 monthly cycles of treatment.

Positive Dose Dependent Biomarker Data: The AvalonRx(R) platform has identified selected biomarkers from pati ent samples which show a correlation of changes in gene expression in a dose dependent manner. Importantly, several of these markers display a durable, sustained stress response indicative of cancer cell death, particularly in cancer cells from AML patients. As dose levels increase the biomarkers reflect an even greater impact of AVN944 on the cancer cells. Direct markers of apoptosis are induced at these higher levels, including members of the Bcl2 gene family which play a critical role in programmed cell death. Additionally, the IMPDH enzyme is inhibited and GTP pools are also depleted for more sustained time periods in treated patients.

Potential Study Stratification Biomarker Data: Additionally we have identified a genetic signature, existing prior to drug exposure, which correlates strongly with disease stabilization in the first cycle of therapy. While still preliminary, based on a small patient sampling, this signature could be the foundation for future patient stratification strategies in phase II and III clinical trials.

Teleconference and Webcast: The company will host a conference call on Wednesday, June 20, 2007 at 8 a.m. Eastern Daylight Time to discuss the interim results of the AVN944 Phase I clinical trial. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the company's Web site or by dialing the numbers listed below. A detailed PowerPoint presentation will accompany the webcast.

    Conference Call Details:

    Dial-In:           (800) 291-5365 (U.S.)

                       (617) 614-3922 (International)

                       Pass code:  74005634

    Webcast:           Please go to, Investor Relations,

                       within 15 minutes prior to the call and select the

                       webcast link.  If listening by phone and viewing 

                       slides, please choose the 'listen via phone' option to

                       view the slides in real time as there is a 30 second

                       delay otherwise. The conference call replay will be

                       available through August 15, 2007 on Avalon's website


About Avalon Pharmaceuticals

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of potential first-in-class cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944), preclinical programs to develop inhibitors for the Beta-catenin and Aurora pathways, discovery programs for Survivin and Myc pathway inhibitors, and value generating partnerships with Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx(R) our platform technology, based upon the proprietary use of large-scale gene expressions, we are uniquely positioned to develop therapeutics focused on pathways that have historically been characterized as "undruggable". Avalon was established in 1999 and is headquartered in Germantown, Md.

About AvalonRx(R)

AvalonRx(R) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response.

Safe Harbor Statement

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncerta inties, in particular, related to clinical progress in the development of AVN944. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties including the risk that AVN944 will not progress successfully in its clinical trials, and other risks described in our SEC filings. There can be no assurance that our development efforts will succeed, that AVN944 will receive required regulatory clearance or, even if such regulatory clearance is received, that any subsequent products will ultimately achieve commercial success. The information in this Release should be read in conjunction with the Risk Factors set forth in our 2006 Annual Report on Form 10-K and updates contained in subsequent filings we make with the SEC.


    Avalon Pharmaceuticals, Inc.                  Russo Partners, LLC

    David D. Muth                                 Wendy Lau (Media)

    Executive Vice President                      Tel: (212) 845-4272

    Chief Business Officer

    Tel: (301) 556-9900                           The Trout Group LLC

    Fax: (301) 556-9910                           Chad Rubin (Investors)

    Email:                       Tel: (646) 378-2947

CONTACT: David D. Muth, Executive Vice President of AvalonPharmaceuticals, Inc., +1-301-556-9900, or fax, +1-301-556-9910,; or media, Wendy Lau of Russo Partners, LLC,+1-212-845-4272, for Avalon Pharmaceuticals, Inc.; or investors, ChadRubin, Chief Business Officer of The Trout Group LLC, +1-646-378-2947

Web site:

Ticker Symbol: (NASDAQ-NMS:AVRX)

Terms and condition s of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 /PRNewswire/ ... of Pro Medicus Ltd. (ASX: PME), has announced that ... University of Florida (UF) have selected the Visage ... diagnostic viewer of the Emergent/Critical Care Imaging SIMulation ... Wisdom in Diagnostic Imaging Program (WIDI), a multi-faceted ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology:
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/10/2016)... ... February 10, 2016 , ... President Obama’s ... Advantage organizations to deliver medical services via telehealth, estimated to generate more than ... for such language for many years. Although there is more to be ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team ... raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from 100% ... farmers and the quality of their product, through activities that focus on better farming, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western ... dental health services to the developmentally disabled in the Coachella Valley. , The ... a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City Health ... (VRI). , For nearly 23 years, Heart City Health Center has provided the ...
Breaking Medicine News(10 mins):